中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

HBV相关肝细胞癌患者抗病毒药物的选择

冯明洋 王晖

引用本文:
Citation:

HBV相关肝细胞癌患者抗病毒药物的选择

DOI: 10.3969/j.issn.1001-5256.2022.11.004
利益冲突声明:所有作者均声明不存在利益冲突。
作者贡献声明:冯明洋负责查找文献、分析资料、撰写文章;王晖负责确定写作思路、指导文章撰写及最后定稿。
详细信息
    通信作者:

    王晖,wanghuirj@163.com

Selection of antiviral drugs for patients with hepatitis B virus-associated hepatocellular carcinoma

More Information
  • 摘要: HBV感染是肝细胞癌(HCC)发生和发展的主要危险因素,通过诱导肝纤维化、遗传和表观遗传改变以及活性病毒编码蛋白的表达来促进HCC的进展。多项研究证实病毒状态影响HCC预后,有效的抗病毒治疗有助于预防或延迟HBV相关HCC复发,提高患者接受根治性或系统性治疗后的总生存期,改善综合治疗预后。因此,正确选择抗病毒药物对于HBV相关HCC患者的抗病毒治疗至关重要。本文就HBV相关HCC患者抗病毒药物的选择进行简要综述,以供临床参考。

     

  • [1] VILLANUEVA A. Hepatocellular carcinoma[J]. N Engl J Med, 2019, 380(15): 1450-1462. DOI: 10.1056/NEJMra1713263.
    [2] LLOVET JM, KELLEY RK, VILLANUEVA A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1): 6. DOI: 10.1038/s41572-020-00240-3.
    [3] ROBERTS SK, MAJEED A, KEMP W. Controversies in the management of hepatitis B: hepatocellular carcinoma[J]. Clin Liver Dis, 2021, 25(4): 785-803. DOI: 10.1016/j.cld.2021.06.006.
    [4] HUNG IF, POON RT, LAI CL, et al. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection[J]. Am J Gastroenterol, 2008, 103(7): 1663-1673. DOI: 10.1111/j.1572-0241.2008.01872.x.
    [5] XIA Z, HE L, XIONG L, et al. The comparison of different antiviral therapies on the prognosis of hepatitis B virus-related hepatocellular carcinoma after curative treatments: A network meta-analysis[J]. Medicine (Baltimore), 2020, 99(33): e20877. DOI: 10.1097/MD.0000000000020877.
    [6] Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [7] Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical Association. Expert consensus on antiviral therapy for HBV/HCV-related hepatocellular carcinoma: A 2021 update[J]. J Clin Hepatol, 2021, 37(10): 2292-2302. DOI: 10.3969/j.issn.1001-5256.2021.10.008.

    中华医学会肝病学分会肝癌学组. HBV/HCV相关肝细胞癌抗病毒治疗专家共识(2021年更新版)[J]. 临床肝胆病杂志, 2021, 37(10): 2292-2302. DOI: 10.3969/j.issn.1001-5256.2021.10.008.
    [8] General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer (2022 edition)[J]. J Clin Hepatol, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.

    国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
    [9] ARZUMANYAN A, REIS HM, FEITELSON MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma[J]. Nat Rev Cancer, 2013, 13(2): 123-135. DOI: 10.1038/nrc3449.
    [10] SARTORIUS K, AN P, WINKLER C, et al. The epigenetic modulation of cancer and immune pathways in hepatitis B virus-associated hepatocellular carcinoma: the influence of HBx and miRNA dysregulation[J]. Front Immunol, 2021, 12: 661204. DOI: 10.3389/fimmu.2021.661204.
    [11] PENG XF, HUANG SF, CHEN LJ, et al. Targeting epigenetics and lncRNAs in liver disease: From mechanisms to therapeutics[J]. Pharmacol Res, 2021, 172: 105846. DOI: 10.1016/j.phrs.2021.105846.
    [12] CHEN L, HUANG W, WANG L, et al. The effects of epigenetic modification on the occurrence and progression of liver diseases and the involved mechanism[J]. Expert Rev Gastroenterol Hepatol, 2020, 14(4): 259-270. DOI: 10.1080/17474124.2020.1736042.
    [13] VEZZANI B, CARINCI M, PREVIATI M, et al. Epigenetic regulation: A link between inflammation and carcinogenesis[J]. Cancers (Basel), 2022, 14(5): 1221. DOI: 10.3390/cancers14051221.
    [14] SUN X, YAN X, SHAO R, et al. Efficacy of antiviral therapy in patients with hepatitis B-related primary liver cancer[J]. J BUON, 2021, 26(3): 897-903.
    [15] WU CY, CHEN YJ, HO HJ, et al. Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection[J]. JAMA, 2012, 308(18): 1906-1914. DOI: 10.1001/2012.jama.11975.
    [16] WANG Y, XIANG X, CHEN L, et al. Randomized clinical trial: Nucleos(t)ide analogues improved survival of CHB-related HCC patients via reducing severity and progression of malignancy[J]. Oncotarget, 2016, 7(36): 58553-58562. DOI: 10.18632/oncotarget.10155.
    [17] WONG JS, WONG GL, TSOI KK, et al. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2011, 33(10): 1104-1112. DOI: 10.1111/j.1365-2036.2011.04634.x.
    [18] YIN J, LI N, HAN Y, et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study[J]. J Clin Oncol, 2013, 31(29): 3647-3655. DOI: 10.1200/JCO.2012.48.5896.
    [19] QI W, SHEN J, DAI J, et al. Comparison of nucleoside and nucleotide analogs in the recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection: A multicenter study[J]. Cancer Med, 2021, 10(23): 8421-8431. DOI: 10.1002/cam4.4348.
    [20] ZHANG X, LI C, WEN T, et al. The different effects of nucleotide and nucleoside analogues on the prognosis of HBV-related HCC after curative resection[J]. J Gastrointest Surg, 2021, 25(6): 1419-1429. DOI: 10.1007/s11605-020-04633-3.
    [21] GUAN RY, SUN BY, WANG ZT, et al. Antiviral therapy improves postoperative survival of patients with HBV-related hepatocellular carcinoma[J]. Am J Surg, 2022, 224(1 Pt B): 494-500. DOI: 10.1016/j.amjsurg.2022.01.008.
    [22] HUANG G, LAU WY, WANG ZG, et al. Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial[J]. Ann Surg, 2015, 261(1): 56-66. DOI: 10.1097/SLA.0000000000000858.
    [23] LEE TY, LIN JT, ZENG YS, et al. Association between nucleos(t)ide analog and tumor recurrence in hepatitis B virus-related hepatocellular carcinoma after radiofrequency ablation[J]. Hepatology, 2016, 63(5): 1517-1527. DOI: 10.1002/hep.28266.
    [24] CHO H, AHN H, LEE DH, et al. Entecavir and tenofovir reduce hepatitis B virus-related hepatocellular carcinoma recurrence more effectively than other antivirals[J]. J Viral Hepat, 2018, 25(6): 707-717. DOI: 10.1111/jvh.12855.
    [25] KIM JH, SINN DH, KIM K, et al. Lamivudine versus entecavir for newly diagnosed hepatitis B virus-related hepatocellular carcinoma[J]. Gut Liver, 2016, 10(6): 939-947. DOI: 10.5009/gnl15527.
    [26] CHOI J, JO C, LIM YS. Tenofovir versus entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection[J]. Hepatology, 2021, 73(2): 661-673. DOI: 10.1002/hep.31289.
    [27] SHEN J, QI W, DAI J, et al. Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy[J]. Chin Med J (Engl), 2021, 135(3): 301-308. DOI: 10.1097/CM9.0000000000001864.
    [28] GE Z, MA J, QIAO B, et al. Impact of tenofovir antiviral treatment on survival of chronic hepatitis B related hepatocellular carcinoma after hepatectomy in Chinese individuals from Qingdao municipality[J]. Medicine (Baltimore), 2020, 99(32): e21454. DOI: 10.1097/MD.0000000000021454.
    [29] TSAI MC, WANG CC, LEE WC, et al. Tenofovir is superior to entecavir on tertiary prevention for BCLC stage 0/A hepatocellular carcinoma after curative resection[J]. Liver Cancer, 2021, 11(1): 22-37. DOI: 10.1159/000518940.
    [30] LEE JH, KIM BK, PARK SY, et al. The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma[J]. Eur J Intern Med, 2021, 89: 48-55. DOI: 10.1016/j.ejim.2021.02.019.
    [31] WANG XH, HU ZL, FU YZ, et al. Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection[J]. J Gastroenterol, 2022, 57(3): 185-198. DOI: 10.1007/s00535-022-01855-x.
    [32] MURATA K, TSUKUDA S, SUIZU F, et al. Immunomodulatory mechanism of acyclic nucleoside phosphates in treatment of hepatitis B virus infection[J]. Hepatology, 2020, 71(5): 1533-1545. DOI: 10.1002/hep.30956.
    [33] ZHANG Y, LI X, ZHANG Y, et al. Pegylated interferon-α inhibits the proliferation of hepatocellular carcinoma cells by downregulating miR-155[J]. Ann Hepatol, 2019, 18(3): 494-500. DOI: 10.1016/j.aohep.2018.11.007.
    [34] ARAKAWA Y, SHIMADA M, UTSUNOMIYA T, et al. Effects of pegylated interferon α 2b on metastasis of hepatocellular carcinoma[J]. J Surg Res, 2012, 172(1): 95-101. DOI: 10.1016/j.jss.2010.07.023.
    [35] XU J, LI J, CHEN J, et al. Effect of adjuvant interferon therapy on hepatitis b/c virus-related hepatocellular carcinoma after curative therapy - meta-analysis[J]. Adv Clin Exp Med, 2015, 24(2): 331-340. DOI: 10.17219/acem/29760.
    [36] YANG S, LIN Q, LIN W, et al. Effect of adjuvant interferon therapy on hepatitis B virus-related hepatocellular carcinoma: a systematic review[J]. World J Surg Oncol, 2016, 14(1): 159. DOI: 10.1186/s12957-016-0912-7.
    [37] ZUO CH, XIA M, LIU JS, et al. Transcatheter arterial chemoembolization combined with interferon-α is safe and effective for patients with hepatocellular carcinoma after curative resection[J]. Asian Pac J Cancer Prev, 2015, 16(1): 245-251. DOI: 10.7314/apjcp.2015.16.1.245.
    [38] WU J, YIN Z, CAO L, et al. Adjuvant pegylated interferon therapy improves the survival outcomes in patients with hepatitis-related hepatocellular carcinoma after curative treatment: A meta-analysis[J]. Medicine (Baltimore), 2018, 97(28): e11295. DOI: 10.1097/MD.0000000000011295.
    [39] HU B, YU M, MA X, et al. IFNα potentiates anti-PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment[J]. Cancer Discov, 2022, 12(7): 1718-1741. DOI: 10.1158/2159-8290.CD-21-1022.
    [40] ZHU Y, CHEN M, XU D, et al. The combination of PD-1 blockade with interferon-α has a synergistic effect on hepatocellular carcinoma[J]. Cell Mol Immunol, 2022, 19(6): 726-737. DOI: 10.1038/s41423-022-00848-3.
    [41] QU LS, JIN F, HUANG XW, et al. Interferon-α therapy after curative resection prevents early recurrence and improves survival in patients with hepatitis B virus-related hepatocellular carcinoma[J]. J Surg Oncol, 2010, 102(7): 796-801. DOI: 10.1002/jso.21741.
    [42] QI W, ZHANG Q, XU Y, et al. Peg-interferon and nucleos(t)ide analogue combination at inception of antiviral therapy improves both anti-HBV efficacy and long-term survival among HBV DNA-positive hepatocellular carcinoma patients after hepatectomy/ablation[J]. J Viral Hepat, 2020, 27(4): 387-396. DOI: 10.1111/jvh.13236.
    [43] QI WQ, ZHANG Q, WANG X, et al. Long-term clinical benefit of Peg-IFNα and NAs sequential anti-viral therapy on HBV related HCC[J]. Neoplasma, 2021, 68(1): 200-207. DOI: 10.4149/neo_2020_200506N493.
  • 加载中
计量
  • 文章访问数:  225
  • HTML全文浏览量:  48
  • PDF下载量:  82
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-09-21
  • 录用日期:  2022-10-21
  • 出版日期:  2022-11-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回